EUVIMEDEUVIMED entdecken
Open Access

Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?

Beibo Zhao, Anastasia Ivanova, Nader Shaikh iD

Pediatric Nephrology · 2024

DOI: 10.1007/s00467-024-06291-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Nephrology, 2024. Verfasst von Beibo Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Vesico-Ureteral Reflux, Anti-Infective Agents, Urinary Tract Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial found that long-term antimicrobial prophylaxis reduced the risk of urinary tract infection (UTI) recurrences by 50%, 10 children had to be treated for one to benefit (i.e., observed number needed to treat (NNT) of 10). Accordingly, we re-analyzed RIVUR data to systematically identify subgroups of children with vesicoureteral reflux (VUR) with a smaller NNT. METHODS: Using patient-level data from the RIVUR trial, we applied penalized regression methods including the baseline age, VUR grade, type of index UTI, and bowel-bladder dysfunction (BBD) as covariates to identify subgroups. RESULTS: We identified four relevant subgroups of children that appear to benefit from long-term antimicrobial prophylaxis, all with observed NNTs smaller than or equal to 5: children with grade IV VUR, BBD, and febrile index UTI (1% of the sample), children with BBD and febrile index UTI (7% of the sample), children with BBD (12% of the sample), and children with grade IV VUR (8% of the sample). CONCLUSIONS: Use of long-term antimicrobial prophylaxis appears to be particularly relevant for children with BBD (and any grade of VUR) and those with grade IV VUR (regardless of BBD status). However, because details regarding the treatment of BBD are not available, further studies are needed to fully determine the role of prophylactic antimicrobials in the management of children with VUR who have BBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vesico-Ureteral RefluxAnti-Infective AgentsUrinary Tract InfectionsChildHumansInfantAntibiotic Prophylaxis

Stichwörter der Autor:innen

EfficacyRiskUrinary tract infection

Substanzen

Anti-Infective Agents

Autor:innen und Institutionen

  • Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
  • School of Medicine, Division of General Academic, University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA. nader.shaikh@chp.edu.

ORCID-Profile: Nader Shaikh

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Zhao, B., Ivanova, A., & Shaikh, N. (2024). Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06291-y

Vancouver

Zhao B, Ivanova A, Shaikh N. Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?. Pediatric Nephrology. 2024. doi:10.1007/s00467-024-06291-y

BibTeX
@article{Zhao2024,
  author = {Zhao, Beibo and Ivanova, Anastasia and Shaikh, Nader},
  title = {Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?},
  journal = {Pediatric Nephrology},
  year = {2024},
  doi = {10.1007/s00467-024-06291-y}
}
Kostenlos starten →